FDA Approves Arzerra (ofatumumab) for Chronic Lymphocytic Leukemia
FDA Approves Arzerra (ofatumumab) for Chronic Lymphocytic Leukemia
October 26, 2009
SILVER SPRING. Md., Oct. 26 /PRNewswire-USNewswire/ -- The U.S. Food
and Drug Administration today approved Arzerra (ofatumumab) for
patients with chronic lymphocytic leukemia (CLL), a slowly progressing
cancer of the blood and bone marrow. Arzerra is approved for patients
with CLL whose cancer is no longer being controlled by other forms of
chemotherapy. CLL primarily affects people older than 50 and arises
from a group of white blood cells known as B-cells that are part of
the body's immune...
October 26, 2009
SILVER SPRING. Md., Oct. 26 /PRNewswire-USNewswire/ -- The U.S. Food
and Drug Administration today approved Arzerra (ofatumumab) for
patients with chronic lymphocytic leukemia (CLL), a slowly progressing
cancer of the blood and bone marrow. Arzerra is approved for patients
with CLL whose cancer is no longer being controlled by other forms of
chemotherapy. CLL primarily affects people older than 50 and arises
from a group of white blood cells known as B-cells that are part of
the body's immune...
Comentarios
Publicar un comentario